SHANGHAI, CHINA and SAN DIEGO, USA, January 4, 2014 – Zensun (Shanghai) Sci. & Tech., Ltd, and its subsidiary Zensun USA, Inc. are pleased to announce the successful completion of an End of Phase 2 (EOP2) Meeting for Neucardin™, an innovative “first-in-class” anti-heart failure drug. Based on the results of the meeting, Zensun believes that they have a clear path to the pivotal Phase 3 program to support a Biologic License Application (BLA) in the U.S, and now Zensun is going to start all necessary preparations for the initiation of the Phase 3 study.